![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/06/26/2904391/0/en/atai-Life-Sciences-to-Participate-in-the-H-C-Wainwright-5th-Annual-Neuro-Perspectives-Conference.html
https://www.globenewswire.com/news-release/2024/06/20/2901566/0/en/atai-Life-Sciences-Announces-Update-on-Beckley-Psytech-s-Phase-1-2a-Trial-of-ELE-101-IV-Psilocin-for-Major-Depressive-Disorder-with-Initial-Results-from-Phase-1-and-First-Patients-.html
https://www.globenewswire.com/news-release/2024/05/31/2891451/0/en/atai-Life-Sciences-to-Participate-in-the-Jefferies-2024-Global-Healthcare-Conference.html
https://www.globenewswire.com/news-release/2024/05/23/2887164/0/en/atai-Life-Sciences-Strengthens-Board-with-Appointment-of-Two-New-Independent-Directors.html
https://www.globenewswire.com/news-release/2024/05/15/2882281/0/en/atai-Life-Sciences-Reports-First-Quarter-2024-Financial-Results-and-Corporate-Updates.html
https://www.globenewswire.com/news-release/2024/04/24/2868477/0/en/atai-Life-Sciences-Announces-Dosing-of-First-Patient-in-Part-2-of-Beckley-Psytech-s-Phase-2a-Study-Exploring-BPL-003-Adjunctive-to-SSRIs-in-Patients-with-Treatment-Resistant-Depres.html
https://www.globenewswire.com/news-release/2024/04/17/2864385/0/en/atai-Life-Sciences-Announces-the-Publication-of-Beckley-Psytech-s-Phase-1-Study-of-BPL-003-in-the-Journal-of-Psychopharmacology.html
https://www.globenewswire.com/news-release/2024/03/28/2853842/0/en/atai-Life-Sciences-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Corporate-and-Clinical-Highlights.html
https://www.globenewswire.com/news-release/2024/03/27/2853041/0/en/atai-Life-Sciences-Announces-Positive-Initial-Results-from-Beckley-Psytech-s-Phase-2a-Open-Label-Study-of-BPL-003-Intranasal-5-MeO-DMT-in-Treatment-Resistant-Depression.html
https://www.intelgenx.com/newsrooms/newsrooms1/134-2024-news/980-ntelenxntersntoahirdmendedandestatedoangr20240311